Back to results
US 2021/0060144 A1Published application
Neurotoxin compositions for use in treating headache
AssigneeAeon Biopharma, Inc.
InventorsGregory F. Brooks, Andrew M. Blumenfeld
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for use in treating Migraine, for example Episodic or Chronic Migraine, including methods with reduced side effects and comparable or improved efficacy as compared to methods known in the art.
Claims38
1) A method for reducing the severity of a symptom associated with a migraine headache comprising:
- a) administering a Clostridial neurotoxin into at least five of the muscle regions selected from the frontalis, corrugator, procerus, masseter, nasalis, oculi, occipitalis, temporalis, and trapezius muscle regions;
- and
- b) thereby reducing the severity of the symptom associated with migraine headache.
37) A method for reducing the severity of a symptom associated with migraine comprising:
- administering a Clostridial toxin to the superior trapezius at a dosage of about 3-10 units per site at two sites on each side of the head and 5-15 units per site to the inferior trapezius at two sites on each side of the head;
- administering a Clostridial toxin to the occipitalis at a dosage of about 7-15 units per site at three sites on each side of the head;
- administering a Clostridial toxin to the temporalis at a dosage of about 3-15 units per site at three sites on each side of the head;
- administering a Clostridial toxin to the oculi at a dosage of about 3-10 units to one site on each side of the head;
- administering a Clostridial toxin to the corrugator at a dosage of about 3-10 units to one site on each side of the head;
- administering a Clostridial toxin to the frontalis at a dosage of about 3-10 units to one site on each side of the head;
- thereby reducing the severity of the symptom associated with migraine.
4 more elements
38) A method for reducing the severity of a symptom associated with Chronic Migraine (CM) comprising:
- administering a Clostridial toxin to the superior trapezius at a dosage of about 3-10 units per site at two sites on each side of the head and 5-15 units per site to the inferior trapezius at two sites on each side of the head;
- administering a Clostridial toxin to the occipitalis at a dosage of about 7-15 units per site at three sites on each side of the head;
- administering a Clostridial toxin to the temporalis at a dosage of about 3-15 units per site at three sites on each side of the head;
- administering a Clostridial toxin to the oculi at a dosage of about 3-10 units to one site on each side of the head;
- administering a Clostridial toxin to the corrugator at a dosage of about 3-10 units to one site on each side of the head;
- administering a Clostridial toxin to the frontalis at a dosage of about 3-10 units to one site on each side of the head;
- administering a Clostridial toxin to the nasalis at a dosage of about 1-5 units to one site on each side of the head;
- administering a Clostridial toxin to the masseter at a dosage of about 3-10 units to one site on each side of the head
- thereby reducing the severity of the symptom associated with CM.
6 more elements
Dependencies are inferred from the claim text.